Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:11190729rdf:typepubmed:Citationlld:pubmed
pubmed-article:11190729lifeskim:mentionsumls-concept:C0005768lld:lifeskim
pubmed-article:11190729lifeskim:mentionsumls-concept:C0005795lld:lifeskim
pubmed-article:11190729lifeskim:mentionsumls-concept:C0005841lld:lifeskim
pubmed-article:11190729lifeskim:mentionsumls-concept:C0205147lld:lifeskim
pubmed-article:11190729lifeskim:mentionsumls-concept:C0003241lld:lifeskim
pubmed-article:11190729lifeskim:mentionsumls-concept:C0033105lld:lifeskim
pubmed-article:11190729lifeskim:mentionsumls-concept:C1522609lld:lifeskim
pubmed-article:11190729lifeskim:mentionsumls-concept:C1554112lld:lifeskim
pubmed-article:11190729pubmed:issue8-9lld:pubmed
pubmed-article:11190729pubmed:dateCreated2001-1-16lld:pubmed
pubmed-article:11190729pubmed:abstractTextDetection of anti-CMV antibodies was carried out in sera of healthy blood donors, divided into groups of 20 according to age and sex. Sera were tested for anti-CMV by an ELISA test (Enzygnost anti-CMV/IgG-Behring). Among 280 sera, 272 were positive for IgG to CMV (97.14%). The prevalence of those antibodies was high in all age stratum (95-100%) but was higher in women than in men (98.57% versus 95.71%). The titre of IgG to CMV was superior to 12 Ul/ml in 56.43% of CMV positive donors. So, the leucocyte removal is the only alternative for the prevention of post-transfusional CMV infection. The high percentage of donors with anti-CMV antibodies level more than to 12 Ul/ml allow to consider the use of plasmapheresis for preparing specific immunoglobulins to CMV.lld:pubmed
pubmed-article:11190729pubmed:languagefrelld:pubmed
pubmed-article:11190729pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:11190729pubmed:citationSubsetIMlld:pubmed
pubmed-article:11190729pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:11190729pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:11190729pubmed:statusMEDLINElld:pubmed
pubmed-article:11190729pubmed:issn0041-4131lld:pubmed
pubmed-article:11190729pubmed:authorpubmed-author:KarrayHHlld:pubmed
pubmed-article:11190729pubmed:authorpubmed-author:HammamiAAlld:pubmed
pubmed-article:11190729pubmed:authorpubmed-author:GargouriJJlld:pubmed
pubmed-article:11190729pubmed:authorpubmed-author:RekikHHlld:pubmed
pubmed-article:11190729pubmed:authorpubmed-author:ElleuchHHlld:pubmed
pubmed-article:11190729pubmed:issnTypePrintlld:pubmed
pubmed-article:11190729pubmed:volume78lld:pubmed
pubmed-article:11190729pubmed:ownerNLMlld:pubmed
pubmed-article:11190729pubmed:authorsCompleteYlld:pubmed
pubmed-article:11190729pubmed:pagination512-7lld:pubmed
pubmed-article:11190729pubmed:dateRevised2006-11-15lld:pubmed
pubmed-article:11190729pubmed:meshHeadingpubmed-meshheading:11190729...lld:pubmed
pubmed-article:11190729pubmed:meshHeadingpubmed-meshheading:11190729...lld:pubmed
pubmed-article:11190729pubmed:meshHeadingpubmed-meshheading:11190729...lld:pubmed
pubmed-article:11190729pubmed:meshHeadingpubmed-meshheading:11190729...lld:pubmed
pubmed-article:11190729pubmed:meshHeadingpubmed-meshheading:11190729...lld:pubmed
pubmed-article:11190729pubmed:meshHeadingpubmed-meshheading:11190729...lld:pubmed
pubmed-article:11190729pubmed:meshHeadingpubmed-meshheading:11190729...lld:pubmed
pubmed-article:11190729pubmed:meshHeadingpubmed-meshheading:11190729...lld:pubmed
pubmed-article:11190729pubmed:meshHeadingpubmed-meshheading:11190729...lld:pubmed
pubmed-article:11190729pubmed:meshHeadingpubmed-meshheading:11190729...lld:pubmed
pubmed-article:11190729pubmed:meshHeadingpubmed-meshheading:11190729...lld:pubmed
pubmed-article:11190729pubmed:meshHeadingpubmed-meshheading:11190729...lld:pubmed
pubmed-article:11190729pubmed:meshHeadingpubmed-meshheading:11190729...lld:pubmed
pubmed-article:11190729pubmed:meshHeadingpubmed-meshheading:11190729...lld:pubmed
pubmed-article:11190729pubmed:meshHeadingpubmed-meshheading:11190729...lld:pubmed
pubmed-article:11190729pubmed:meshHeadingpubmed-meshheading:11190729...lld:pubmed
pubmed-article:11190729pubmed:meshHeadingpubmed-meshheading:11190729...lld:pubmed
pubmed-article:11190729pubmed:meshHeadingpubmed-meshheading:11190729...lld:pubmed
pubmed-article:11190729pubmed:articleTitle[Prevalence of anti-CMV antibodies in blood donors in the Sfax region (value in blood transfusion)].lld:pubmed
pubmed-article:11190729pubmed:affiliationCentre Régional de Transfusion Sanguine de Sfax.lld:pubmed
pubmed-article:11190729pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:11190729pubmed:publicationTypeEnglish Abstractlld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:11190729lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:11190729lld:pubmed